ESSA Pharma Reports Q3 Earnings: Revenue Down 3% YOY, Operating Expenses Up 17%

ESSA Pharma Inc. (EPIX) held a shareholder/analyst call on October 3, 2025. David Parkinson, President and CEO, and David Wood, CFO, presented. The call focused on the company's progress and future prospects.

On October 3, 2025, ESSA Pharma Inc. (NASDAQ: EPIX) held a shareholder/analyst call to discuss the company's progress and future prospects. The call was led by David Parkinson, President and CEO, and David Wood, Chief Financial Officer. The meeting was conducted virtually and featured a detailed presentation and a Q&A session with attendees.

Key Points from the Call:

1. Business Combination with XenoTherapeutics Inc.
ESSA announced that it received an amended Interim Order from the Supreme Court of British Columbia, approving the date for its special meeting of shareholders and optionholders. The company is set to merge with XenoTherapeutics Inc., a non-profit biotechnology company focused on advancing xenotransplantation ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order^[2].

2. Special Meeting Details
The special meeting, scheduled for October 3, 2025, will be held online via a live interactive webcast. Shareholders and optionholders are encouraged to participate and vote electronically through the Computershare platform. The meeting will reconvene at 2:00 p.m. (Pacific Time) on October 3, 2025 ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order^[2].

3. Forward-Looking Statements
The call included several forward-looking statements regarding the anticipated completion of the business combination and its potential benefits. These statements are subject to risks and uncertainties, including regulatory approvals, potential litigation, and competitive responses ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order^[2].

4. Q&A Session
During the Q&A session, investors and analysts posed questions about the company's financial performance, the progress of the business combination, and the potential impact of the transaction on ESSA's operations. The executives provided detailed responses, addressing concerns and providing insights into the company's strategy.

Conclusion:
The shareholder/analyst call provided valuable insights into ESSA Pharma Inc.'s current state and future plans. The company's progress in the business combination with XenoTherapeutics Inc. and the details of the upcoming special meeting were highlighted. Investors and financial professionals will continue to monitor ESSA's developments as it moves forward with its strategic initiatives.